1
40
4
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1007/s40674-019-00129-7" target="_blank" rel="noreferrer noopener">http://doi.org/10.1007/s40674-019-00129-7</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
290
Issue
4
Volume
5
ISSN
2198-6002
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<a href="http://ezproxy.neomed.idm.oclc.org/login?url=http://doi.org/10.1007/s40674-019-00129-7" target="_blank" rel="noreferrer noopener">NEOMED Full-text Holding (if available) - Proxy DOI: 10.1007/s40674-019-00129-7</a>
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Update Year & Number
January 2020 Update
NEOMED College
NEOMED College of Medicine
NEOMED Department
NEOMED Student Publications; NEOMED College of Medicine Student
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Adverse Cutaneous Reactions of Common Biologic Medications for Rheumatic Diseases
Publisher
An entity responsible for making the resource available
Current Treatment Options in Rheumatology
Date
A point or period of time associated with an event in the lifecycle of the resource
2019
1905-07
Subject
The topic of the resource
Adverse cutaneous effects; Biologics; Infusion reaction; Rheumatic diseases
Creator
An entity primarily responsible for making the resource
Khanna Urmi; Ellis Ariana M; Fernandez Anthony P
Description
An account of the resource
Purpose of Review: Within the last two decades, the application of biologic medications for rheumatic diseases has greatly expanded. Therefore, it is important for clinicians to be knowledgeable about potential adverse reactions of this medication class. The goal of this review is to discuss the current understanding of cutaneous adverse reactions that may occur with common biologic medications utilized in the management of rheumatic diseases.Recent Findings: A variety of cutaneous reactions have been reported in association with biologics commonly used to treat rheumatic diseases. Here, we review cutaneous reactions reported with tumor necrosis factor-α inhibitors, abatacept (co-stimulation blockade), CD20 inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, and IL-6 inhibitors. The side effects, in most cases, can be managed without discontinuation of the associated biologic medication. However, there are identified reactions that warrant discontinuation or adjustments in order to prevent additional and possibly permanent patient morbidity.Summary: While causation is often difficult to prove when cutaneous side effects are observed in relation to biologic therapies, it is important for clinicians to be aware of characteristic or distinguishing cutaneous reactions in order to treat patients with rheumatic diseases safely and effectively.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1007/s40674-019-00129-7" target="_blank" rel="noreferrer noopener">10.1007/s40674-019-00129-7</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2019
Adverse cutaneous effects
Biologics
Current Treatment Options in Rheumatology
Ellis Ariana M
Fernandez Anthony P
Infusion reaction
January 2020 Update
Journal Article
Khanna Urmi
NEOMED College of Medicine Student
NEOMED Student Publications
rheumatic diseases
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.jaad.2020.01.012" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.jaad.2020.01.012</a>
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<a href="http://ezproxy.neomed.idm.oclc.org/login?url=http://doi.org/10.1016/j.jaad.2020.01.012" target="_blank" rel="noreferrer noopener">NEOMED Full-text Holding (if available) - Proxy DOI: 10.1016/j.jaad.2020.01.012</a>
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Update Year & Number
March 2020 Update
NEOMED College
NEOMED College of Medicine
NEOMED Department
NEOMED Student Publications
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Conversion to Positive Latent Tuberculosis Infection Status is Low in Hidradenitis Suppurativa Patients Taking Biologic Medications.
Publisher
An entity responsible for making the resource available
Journal of the American Academy of Dermatology
Date
A point or period of time associated with an event in the lifecycle of the resource
2020
2020-01
Subject
The topic of the resource
biologics; Hidradenitis Suppurativa; latent tuberculosis; Quantiferon; TNF inhibitors
Creator
An entity primarily responsible for making the resource
Ellis Ariana; Khanna Urmi; Galadari AbdulAziz; Fernandez Anthony
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.jaad.2020.01.012" target="_blank" rel="noreferrer noopener">10.1016/j.jaad.2020.01.012</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2020
Biologics
Ellis Ariana
Fernandez Anthony
Galadari AbdulAziz
Hidradenitis Suppurativa
Journal of the American Academy of Dermatology
Khanna Urmi
latent tuberculosis
NEOMED College of Medicine Student
NEOMED Student Publications
Quantiferon
TNF inhibitors
-
Hyperlink
A link, or reference, to another resource on the Internet.
URL
https://doi.org/10.1016/j.amjoto.2022.103576
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Use of biologics for treatment of autoimmune inner ear disease
Creator
An entity primarily responsible for making the resource
Bailey Balouch
Ryan Meehan
Aishwarya Suresh
Haniah A Zaheer
Abdur Rahman Jabir
Anas M Qatanani
Vishal Suresh
Syed Z Kaleem
Brian J McKinnon
Date
A point or period of time associated with an event in the lifecycle of the resource
2022
Description
An account of the resource
Objective: Biologic medications are novel therapeutics in the treatment of Autoimmune Inner Ear Disease (AIED), an etiology of Sensorineural Hearing Loss (SNHL). The goal of this study is to review the currently available literature on the efficacy of biologic medications on autoimmune-mediated hearing loss and associated symptomology among patients with AIED.
Methods: A systematic review of Pubmed, Scopus, Cochrane, and Web of Science databases was conducted to identify studies investigating the impact of biologic medications on hearing outcomes. Bias assessment was independently conducted by three authors and studies were stratified based on risk of bias.
Results: Of 174 unique abstracts screened, 12 articles met inclusion criteria for formal review. One randomized control trial, seven prospective cohort studies, and four retrospective cohort studies were included. Seven biologic medications, Etanercept, Infliximab, Adalimumab, Golimumab, Rituximab, Anakinra, and Canakinumab, were identified targeting three unique molecular targets, TNF-α, CD20, and IL-1.
Conclusion: The effects of biologic medications in treating SNHL was highly variable without clear efficacy of a drug or drug category, likely due to rarity of disease, multifactorial etiologies of AIED, and cohort heterogeneity. However, several medications alleviate symptoms associated with AIED, such as vertigo and tinnitus. While biologic medications may be promising therapeutics in AIED patients, the evidence is currently inconclusive. Large-scale randomized control trials and prospective cohort reviews are required to establish the efficacy of biologic medications in treating hearing loss.
Source
A related resource from which the described resource is derived
Am J Otolaryngol
. 2022 Sep-Oct;43(5):103576. doi: 10.1016/j.amjoto.2022.103576. Epub 2022 Aug 5.
Language
A language of the resource
English
2022
Biologics
CD20 inhibitors
IL-1 inhibitors
SENSORINEURAL hearing loss
TNF-inhibitors.
-
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Equity in the usage of biologics for psoriasis in the working poor
Creator
An entity primarily responsible for making the resource
Sarah J Eley
Dustin P DeMeo
Neil J Korman
Bryan T Carroll
Date
A point or period of time associated with an event in the lifecycle of the resource
2022
Description
An account of the resource
Biologic therapy often produces excellent outcomes for psoriasis; however, their high cost may create a barrier to appropriate usage, especially in the working poor population. This study defines working poor as income below 150% of the federal poverty level and holding or seeking work at least half a year. Our study aims to identify gaps in access to biologic therapy for psoriasis based on working poor status. This retrospective cross-sectional study was conducted utilizing data from the Medical Expenditure Panel Survey (MEPS) from 2007 to 2018. Patients were stratified into working poor (57,091), non-working poor (43,421), and non-poor (693,841) groups for analysis. In univariate analysis, WP (4.0%, ph p = 0.003) and NWP (2.8%, ph p = 0.006) were less likely to use biologics than NP (15.8%) (X2 p < 0.001). A binary logistic regression showed that WP vs. NP status (OR 0.27, p = 0.05), female vs. male sex (OR 0.55, p = 0.05), Black vs. White race (OR 0.14, p = 0.02), and Medicare vs. private insurance (OR 0.09, p = 0.03) had lower odds of using biologics. After correcting for age, sex, race, and insurance, WP confers an independent risk factor to lower biologic prescriptions. The high cost of biologics in the setting of financial barriers for some patients should be considered by physicians prescribing biologic therapy for psoriasis.
Source
A related resource from which the described resource is derived
Arch Dermatol Res
. 2022 Oct 28. doi: 10.1007/s00403-022-02410-7. Online ahead of print.
Language
A language of the resource
English
2022
Biologics
Equity
psoriasis
Socioeconomics
Working poor.